These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 8382034)

  • 1. The role of histidine-1 in glucagon action.
    Unson CG; Macdonald D; Merrifield RB
    Arch Biochem Biophys; 1993 Feb; 300(2):747-50. PubMed ID: 8382034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of phenylalanine at position 6 in glucagon's mechanism of biological action: multiple replacement analogues of glucagon.
    Azizeh BY; Ahn JM; Caspari R; Shenderovich MD; Trivedi D; Hruby VJ
    J Med Chem; 1997 Aug; 40(16):2555-62. PubMed ID: 9258362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topographical amino acid substitution in position 10 of glucagon leads to antagonists/partial agonists with greater binding differences.
    Azizeh BY; Shenderovich MD; Trivedi D; Li G; Sturm NS; Hruby VJ
    J Med Chem; 1996 Jun; 39(13):2449-55. PubMed ID: 8691441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-function studies on positions 17, 18, and 21 replacement analogues of glucagon: the importance of charged residues and salt bridges in glucagon biological activity.
    Sturm NS; Lin Y; Burley SK; Krstenansky JL; Ahn JM; Azizeh BY; Trivedi D; Hruby VJ
    J Med Chem; 1998 Jul; 41(15):2693-700. PubMed ID: 9667960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age related changes of glucagon binding and activity in isolated rat hepatocytes.
    Poli G; Cassader M; Chiarpotto E; Biasi F; Cecchini G; Pagano G
    Int J Tissue React; 1986; 8(5):367-71. PubMed ID: 3023252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roles of aspartic acid 15 and 21 in glucagon action: receptor anchor and surrogates for aspartic acid 9.
    Unson CG; Wu CR; Merrifield RB
    Biochemistry; 1994 Jun; 33(22):6884-7. PubMed ID: 8204623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conformational considerations in the design of glucagon agonists and antagonists: examination using synthetic analogs.
    Hruby VJ; Krstenansky J; Gysin B; Pelton JT; Trivedi D; Mckee RL
    Biopolymers; 1986; 25 Suppl():S135-55. PubMed ID: 3022837
    [No Abstract]   [Full Text] [Related]  

  • 8. Semisynthetic D-His1,N epsilon-acetimidoglucagon: structure-function relationships.
    Mahrenholz AM; Flanders KC; Hoosein NM; Gurd FR; Gurd RS
    Arch Biochem Biophys; 1987 Sep; 257(2):379-86. PubMed ID: 2821912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of an essential serine residue in glucagon: implication for an active site triad.
    Unson CG; Merrifield RB
    Proc Natl Acad Sci U S A; 1994 Jan; 91(2):454-8. PubMed ID: 8290548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon antagonists: contribution to binding and activity of the amino-terminal sequence 1-5, position 12, and the putative alpha-helical segment 19-27.
    Unson CG; Gurzenda EM; Iwasa K; Merrifield RB
    J Biol Chem; 1989 Jan; 264(2):789-94. PubMed ID: 2536024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increase in stimulatory G protein and glucagon-responsive adenylate cyclase activity in rat liver following partial hepatectomy.
    Yagami T
    Biochem Mol Biol Int; 1994 Jan; 32(1):159-66. PubMed ID: 8012281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Glucagon receptor binding and its effect on the cAMP level in isolated rat and chicken hepatocytes].
    Leĭbush BN; Ukhanova MV
    Fiziol Zh SSSR Im I M Sechenova; 1990 Sep; 76(9):1153-8. PubMed ID: 1963855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Position 9 replacement analogs of glucagon uncouple biological activity and receptor binding.
    Unson CG; Macdonald D; Ray K; Durrah TL; Merrifield RB
    J Biol Chem; 1991 Feb; 266(5):2763-6. PubMed ID: 1847133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptor occupancy and adenylate cyclase activation in rat liver and heart membranes by 10 glucagon analogs modified in position 2,3, 4, 25, 27 and/or 29.
    Robberect P; Damien C; Moroder L; Coy DH; Wünsch E; Christophe J
    Regul Pept; 1988 May; 21(1-2):117-28. PubMed ID: 2839870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthetic peptide antagonists of glucagon.
    Unson CG; Andreu D; Gurzenda EM; Merrifield RB
    Proc Natl Acad Sci U S A; 1987 Jun; 84(12):4083-7. PubMed ID: 3035568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy of seven synthetic glucagon analogs, modified in position 1, 2 and/or 12, on liver and heart adenylate cyclase from rat.
    Robberecht P; Waelbroeck M; Camus JC; De Neef P; Coy DH; Christophe J
    Peptides; 1986; 7 Suppl 1():109-12. PubMed ID: 3018688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of neonatal nutrition on glucagon binding and glucagon stimulated cAMP production in isolated rat hepatocytes.
    Ficková M; Macho L
    Endocrinol Exp; 1988 Sep; 22(3):131-41. PubMed ID: 2851436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ligand-mediated internalization of glucagon receptors in intact rat liver.
    Authier F; Desbuquois B; De Galle B
    Endocrinology; 1992 Jul; 131(1):447-57. PubMed ID: 1319325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Receptor binding and adenylate cyclase activities of glucagon analogues modified in the N-terminal region.
    McKee RL; Pelton JT; Trivedi D; Johnson DG; Coy DH; Sueiras-Diaz J; Hruby VJ
    Biochemistry; 1986 Apr; 25(7):1650-6. PubMed ID: 3011069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic linear and cyclic glucagon antagonists.
    Dharanipragada R; Trivedi D; Bannister A; Siegel M; Tourwe D; Mollova N; Schram K; Hruby VJ
    Int J Pept Protein Res; 1993 Jul; 42(1):68-77. PubMed ID: 8396562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.